Aurobindo Pharma USA Gets FTC Approval to Acquire Lannett for $250M

Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma Ltd, has received approval from the U.S. Federal Trade Commission (FTC) to acquire Lannett Company LLC for $250 million on a cash-free, debt-free basis. The acquisition is expected to close by the end of June 2026. Lannett specializes in complex, non-opioid controlled substances and possesses a U.S.-based manufacturing facility in Seymour, Indiana, with a capacity of 4 billion doses annually. This move is anticipated to expand Aurobindo USA's product offerings, strengthen its domestic manufacturing, and be immediately accretive to earnings per share. The deal is expected to yield significant cost efficiencies, SG&A synergies, and operational integration advantages, supporting long-term growth.